Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Abeona Therapeutics (NASDAQ:ABEO) and maintained a $36 price target.
April 23, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Abeona Therapeutics and maintained a $36 price target.
The reiteration of an Overweight rating and a high price target of $36 by a reputable analyst from Cantor Fitzgerald suggests a strong bullish outlook for Abeona Therapeutics. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100